KARUNA THERAPEUTICS INC (KRTX) Stock Price, Quote, News and Overview
NASDAQ:KRTX - Nasdaq - US48576A1007 - Common Stock - Currency: USD
KRTX Quote, Performance and Key Statistics
329.83
+0.09 (+0.03%)
The current stock price of KRTX is 329.83 USD. In the past month the price increased by 3.27%. In the past year, price increased by 72.12%.
KRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KRTX
Company Profile
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2019-06-28. The firm creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline is primarily built on the therapeutic potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS), and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. The firm is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease (AD). The firm is also engaged in developing its investigational TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and plan to provide details regarding the expected development of KAR-2618.
Company Info
KARUNA THERAPEUTICS INC
99 High Street, 26th Floor
Boston MASSACHUSETTS 02110 US
CEO: Steven Paul
Employees: 210
Company Website: https://karunatx.com/
Phone: 18574492244
KARUNA THERAPEUTICS INC / KRTX FAQ
What is the stock price of KARUNA THERAPEUTICS INC today?
The current stock price of KRTX is 329.83 USD. The price increased by 0.03% in the last trading session.
What is the ticker symbol for KARUNA THERAPEUTICS INC stock?
The exchange symbol of KARUNA THERAPEUTICS INC is KRTX and it is listed on the Nasdaq exchange.
On which exchange is KRTX stock listed?
KRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KARUNA THERAPEUTICS INC stock?
23 analysts have analysed KRTX and the average price target is 329.12 USD. This implies a price decrease of -0.22% is expected in the next year compared to the current price of 329.83. Check the KARUNA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KARUNA THERAPEUTICS INC worth?
KARUNA THERAPEUTICS INC (KRTX) has a market capitalization of 12.58B USD. This makes KRTX a Large Cap stock.
How many employees does KARUNA THERAPEUTICS INC have?
KARUNA THERAPEUTICS INC (KRTX) currently has 210 employees.
What are the support and resistance levels for KARUNA THERAPEUTICS INC (KRTX) stock?
KARUNA THERAPEUTICS INC (KRTX) has a support level at 321.59. Check the full technical report for a detailed analysis of KRTX support and resistance levels.
Is KARUNA THERAPEUTICS INC (KRTX) expected to grow?
The Revenue of KARUNA THERAPEUTICS INC (KRTX) is expected to grow by 1701.02% in the next year. Check the estimates tab for more information on the KRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KARUNA THERAPEUTICS INC (KRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KRTX, evaluating the profitability, health, valuation and growth aspects
- KARUNA THERAPEUTICS INC (KRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KARUNA THERAPEUTICS INC (KRTX) Sales and EPS estimates to see what analysts future expectations are.
- KARUNA THERAPEUTICS INC (KRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KARUNA THERAPEUTICS INC (KRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- KARUNA THERAPEUTICS INC (KRTX) Stock Chart to make your own analysis
- KARUNA THERAPEUTICS INC (KRTX) Latest news and press-releases to stay up to date.
Does KARUNA THERAPEUTICS INC (KRTX) stock pay dividends?
KRTX does not pay a dividend.
When does KARUNA THERAPEUTICS INC (KRTX) report earnings?
KARUNA THERAPEUTICS INC (KRTX) will report earnings on 2024-05-02, after the market close.
What is the Price/Earnings (PE) ratio of KARUNA THERAPEUTICS INC (KRTX)?
KARUNA THERAPEUTICS INC (KRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.72).
KRTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KRTX. When comparing the yearly performance of all stocks, KRTX is one of the better performing stocks in the market, outperforming 94.34% of all stocks.
KRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRTX. While KRTX has a great health rating, there are worries on its profitability.
KRTX Financial Highlights
Over the last trailing twelve months KRTX reported a non-GAAP Earnings per Share(EPS) of -11.72. The EPS decreased by -34.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.46% | ||
| ROE | -34.58% | ||
| Debt/Equity | 0 |
KRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to KRTX. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of -5.2% and a revenue growth 1701.02% for KRTX